# Digest Post: Insights on Recent Cannabis Clinical Observations > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-clinical-observations-recent-studies-digest/ > **Published:** 2026-07-25T23:48:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:02:21-04:00 > **Clinical Summary:** Explore cannabis clinical observations from recent studies covering safety, measurement, and mechanisms to inform research and clinical understanding. --- CED Clinical Relevance #65 Interesting Signals, Evidence-Limited The set is broad and scientifically useful, but it contains no definitive human efficacy trial and requires explicit separation of clinical observations from preclinical and mechanistic evidence. Clinical Insight | CED Clinic The most clinically useful pattern is not a common therapeutic effect. It is the need to identify what each paper actually measured. Two case reports can sharpen differential diagnosis and perioperative history-taking but cannot estimate risk or efficacy. A questionnaire and a laboratory methods paper may improve future measurement without answering whether cannabis helps patients. The animal studies and reviews generate mechanisms and research directions, but they do not support human dosing or treatment recommendations. Digest10 StudiesSafetyMethodsMechanisms Audience Patients, clinicians, caregivers, researchers, laboratorians, and readers following emerging cannabis science. Primary Topic Ten recent peer-reviewed cannabis and cannabinoid studies spanning clinical observations, measurement, safety testing, animal models, and mechanistic reviews. Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42491286/) Table of Contents - [Digest Post: 10 interesting recent studies](#Digest_Post_10_interesting_recent_studies) - [How to Read Ten Different Study Designs Without Overstating Them](#How_to_Read_Ten_Different_Study_Designs_Without_Overstating_Them)[Four checks for a careful reading](#Four_checks_for_a_careful_reading) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Ask What Kind of Evidence This Is](#Ask_What_Kind_of_Evidence_This_Is) - [Use Signals to Improve the History](#Use_Signals_to_Improve_the_History) - [Measurement Quality Matters](#Measurement_Quality_Matters) - [Animal Transfer Is Not a Human Threshold](#Animal_Transfer_Is_Not_a_Human_Threshold) - [Models Test Plausibility](#Models_Test_Plausibility) - [Commercial Interest Exceeds Clinical Evidence](#Commercial_Interest_Exceeds_Clinical_Evidence) - [Promising Is Not Proven](#Promising_Is_Not_Proven) - [Move Toward Comparative Human Outcomes](#Move_Toward_Comparative_Human_Outcomes) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Digest Post: 10 interesting recent studies Ten recent peer-reviewed papers span cannabinoid hyperemesis, perioperative safety, chronic-pain measurement, cannabis testing, prenatal exposure, neurodevelopment, CBD, liver biology, and cannabichromene. Most are case-based, methodological, preclinical, or review evidence, so they should inform questions and future research rather than treatment claims. What This Study Teaches Us Recent cannabis science is advancing across clinical recognition, exposure measurement, laboratory testing, developmental models, and cannabinoid mechanisms. The evidence remains highly heterogeneous, and none of these ten papers establishes a new cannabinoid treatment standard. Why This Matters Readers frequently encounter mechanistic or preclinical findings presented as if they were treatment results. Keeping design, species, comparator, and measured outcome visible makes the science more useful and reduces overclaiming. Study Snapshot Post Type Cannabis Science digest using the canonical CED layout Batch ID e7c3234017d00008 Curated Set 10 verified, nonduplicate peer-reviewed studies Human Clinical Observations 2 case reports Human Measurement Research 1 questionnaire reliability study Laboratory Methods 1 cannabis heavy-metal testing study Animal and Translational Studies 4 studies Mechanistic Reviews 2 reviews Primary Identifiers 42491286, 42465143, 42467034, 42444053, 42494315, 42463640, 42476954, 42475352, 42474488, 42464425 Related Reading 3 verified CED Clinic internal links Clinical Bottom Line These ten studies are interesting because they improve recognition, measurement, laboratory methods, and biological hypotheses. They do not prove that capsaicin is universally effective for cannabinoid hyperemesis, quantify perioperative cannabis risk, or establish CBD, CB2 targeting, or CBC as human treatments. How to Read This Ten-Study Watchlist These papers address different questions: acute clinical observations, measurement reliability, laboratory methods, animal models, and mechanistic reviews. They are grouped to preserve useful research signals, not because they provide a single level of evidence or support a shared treatment conclusion. Study 1 | Topical capsaicin in refractory cannabinoid hyperemesis syndrome Article: Successful Management of Refractory Cannabinoid Hyperemesis Syndrome With Topical Capsaicin: A Case Report With Proposed Mechanism of Action and Literature Review. Authors / source / date / lane: Muhammad Ilyas, Anushka Fernando, and colleagues; Clinical medicine insights. Case reports; 2026; Evidence Check. PMID 42491286; DOI 10.1177/11795476261470568. What was investigated: a single 28-year-old man with heavy daily cannabis use, recurrent cannabinoid hyperemesis syndrome, and vomiting that persisted despite fluids and standard antiemetics. Apparent findings: after abdominal application of 0.1% capsaicin cream, retching stopped within 10 minutes and symptoms resolved over 90 minutes, with transient local burning. Limitations and uncertainty: this is one case, without randomization or a control group. Spontaneous improvement and concurrent care cannot be excluded, and the report cannot establish optimal dosing, comparative effectiveness, or long-term benefit. Why noteworthy: it illustrates a plausible emergency-department adjunct while reinforcing that cannabis cessation remains central and that controlled evidence is still needed. Study 2 | Postoperative hypoxemia after heavy cannabis vaping Article: Transient Postoperative Hypoxemia Associated With Cannabis Use Following General Anesthesia. Authors / source / date / lane: Shairko Missouri, Osman Elsiddig, Jessica Perkins; Cureus; 2026Jun; Research Brief. PMID 42465143; DOI 10.7759/cureus.110926. What was investigated: a young patient with heavy cannabis vaping exposure who developed transient hypoxemia after general anesthesia despite no known cardiopulmonary disease. Apparent findings: the patient required supplemental oxygen and recovered within 24 hours; the authors discuss airway irritation and impaired gas exchange as possible contributors. Limitations and uncertainty: a case report cannot establish that cannabis caused the event. General anesthesia, atelectasis, individual susceptibility, and unmeasured factors remain alternative explanations. Why noteworthy: it supports asking specifically about inhaled and vaped cannabis during preoperative assessment without converting a single event into a general risk estimate. Study 3 | A questionnaire for cannabis use in chronic pain Article: Reliability of a Self-Reported Questionnaire Assessing the Use of Cannabis Products to Treat Chronic Pain. Authors / source / date / lane: Edeltraut Kröger, Clermont E Dionne, and colleagues; Journal of perianesthesia nursing: official journal of the American Society of PeriAnesthesia Nurses; 2026Jul16; Evidence Check. PMID 42467034; DOI 10.1016/j.jopan.2026.06.014. What was investigated: the development and test-retest reliability of a 24-item questionnaire covering pain conditions, cannabis products, routes, cannabinoid concentrations, and other pain therapies in 158 participants. Apparent findings: most items showed high reliability, while questions about pain type and cannabinoid type showed only moderate reliability. Limitations and uncertainty: reliability means that answers were reasonably repeatable, not that self-reports were objectively accurate or that cannabis improved pain. Why noteworthy: better exposure measurement can improve clinical histories and research quality, especially when product and route details are often missing. Study 4 | Resource-efficient heavy-metal testing in cannabis Article: Leveraging Limited Runs for Robust Information: A Resource-Efficient ICP-MS Approach for As, Cd, Pb, and Hg in Cannabis. Authors / source / date / lane: Daniel Arias Ramirez, Juan Mutis Gonzales, Chiara Carazzone; Drug testing and analysis; 2026Jul13; Safety Signal. PMID 42444053; DOI 10.1002/dta.70118. What was investigated: a limited-run ICP-MS screening strategy for arsenic, cadmium, lead, and mercury in spiked cannabis inflorescence samples. Apparent findings: instrument settings and digestion factors influenced robustness and element recovery, narrowing the experimental space for future method optimization. Limitations and uncertainty: the resolution-III design aliases main effects with interactions. The results are screening estimates that require higher-resolution confirmation and full validation. Why noteworthy: laboratory method quality directly affects whether contamination testing produces trustworthy results in resource-limited settings. Study 5 | THC transfer in prenatal prairie-vole and rat models Article: Innovative Methods for Prenatal Cannabis Exposure: Vapor Inhalation Chamber and Metabolite Quantification in Prairie Voles and Rats. Authors / source / date / lane: Sophia Rogers, Casey E Hogrefe, and colleagues; Developmental psychobiology; 2026Jul; Mechanism Watch. PMID 42494315; DOI 10.1002/dev.70185. What was investigated: a standardized vaporized-THC exposure method in pregnant prairie voles and rats, with maternal plasma and fetal brain concentrations measured by LC-MS/MS. Apparent findings: THC crossed the placenta in both species and was measurable in fetal brain tissue, with species-specific concentration patterns. Limitations and uncertainty: this is an animal exposure-methods study. It does not quantify human pregnancy risk, neurodevelopmental outcomes, or a safe level of prenatal exposure. Why noteworthy: the work may improve cross-species prenatal [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) while underscoring that exposure measurements are not human clinical outcomes. Study 6 | Adolescent THC in a dual-hit mouse model of schizophrenia Article: Disruption of Reelin signaling in a dual-hit mouse model of schizophrenia: impact of postnatal Δ9-tetrahydrocannabinol exposure in a maternal immune activation model. Authors / source / date / lane: Celia Martín-Cuevas, Víctor Darío Ramos-Herrero, and colleagues; Translational psychiatry; 2026Jul16; Mechanism Watch. PMID 42463640; DOI 10.1038/s41398-026-04282-1. What was investigated: maternal immune activation followed by adolescent THC exposure in mice, with behavioral, structural, and Reelin-pathway measurements. Apparent findings: THC exposure was associated with cortical and Reelin-related changes, while combined exposures produced selective, sex-dependent schizophrenia-relevant phenotypes. Limitations and uncertainty: mouse behaviors and molecular changes cannot diagnose schizophrenia or predict an individual human outcome. The model tests biological plausibility, not clinical causation. Why noteworthy: it offers a mechanistic framework for studying timing, sex, and interacting developmental risks without proving that THC alone causes schizophrenia. Study 7 | CBD and memory in ovariectomized rats Article: Effects of cannabidiol in comparison to hormonal therapy on estrogen decline-induced memory impairments and [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in rats. Authors / source / date / lane: Fernanda Borsatto Caruso, Maria Paula Arakaki Severo, and colleagues; Journal of neuroendocrinology; 2026Jul; Mechanism Watch. PMID 42476954; DOI 10.1111/jne.70234. What was investigated: CBD, estradiol, or vehicle over 21 days in ovariectomized and sham-operated female rats, with memory tasks and hippocampal endocannabinoid measurements. Apparent findings: CBD and estradiol produced similar improvements in the tested memory tasks and altered endocannabinoid-related enzymes and ligands. Limitations and uncertainty: this was a rat model using injected CBD. It does not show that CBD treats menopause-related cognitive symptoms in humans or that it is equivalent to hormone therapy. Why noteworthy: the study identifies testable mechanisms for future work while making the translational gap unusually important. Study 8 | Chronic CBD in aged HIV-1 Tat transgenic mice Article: Chronic CBD treatment differentially modulates neurobehavioral outcomes and endocannabinoid signaling in an aged HIV-1 Tat transgenic mouse model. Authors / source / date / lane: Barkha J Yadav-Samudrala, Morgan L Johnson, and colleagues; PloS one; 2026; Mechanism Watch. PMID 42475352; DOI 10.1371/journal.pone.0353267. What was investigated: 12 weeks of CBD in aged male and female HIV-1 Tat transgenic mice, with behavioral tests and region-specific endocannabinoid signaling measurements. Apparent findings: recognition memory improved only in female Tat-positive mice, while temperature, pain sensitivity, body mass, and signaling changes varied by sex, genotype, and brain region. Limitations and uncertainty: the transgenic mouse model does not establish efficacy or safety in older people living with HIV. Multiple interactions also increase the risk of unstable or context-specific findings. Why noteworthy: the results argue against treating CBD effects as uniform across sex, age, disease model, dose, or biological compartment. Study 9 | CB2 signaling in [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) and fibrosis Article: Revisiting cannabinoid receptor-2: a key regulator of hepatic steatosis, inflammatory cascades, and fibrotic progression. Authors / source / date / lane: Shilpa Kumari, Biswanath Nayak, and colleagues; Archives of toxicology; 2026Jul20; Mechanism Watch. PMID 42474488; DOI 10.1007/s00204-026-04499-5. What was investigated: a review of cannabinoid receptor 2 signaling across hepatic lipid metabolism, inflammation, and fibrosis. Apparent findings: the review describes preclinical evidence suggesting cell-specific anti-steatotic, anti-inflammatory, and anti-fibrotic actions of CB2 activation. Limitations and uncertainty: mechanistic and preclinical plausibility does not establish that a CB2-targeting drug safely treats metabolic liver disease in humans. Why noteworthy: it maps an active therapeutic target while showing how much clinical validation remains before treatment claims are justified. Study 10 | What is actually known about cannabichromene Article: Cannabichromene (CBC): a comprehensive review of biosynthesis, pharmacology, therapeutic potential, and translational perspectives. Authors / source / date / lane: Amine Elbouzidi, Abdellah Baraich, and colleagues; Journal of [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/); 2026Jul16; Mechanism Watch. PMID 42464425; DOI 10.1186/s42238-026-00454-4. What was investigated: a comprehensive review of cannabichromene biosynthesis, pharmacology, pharmacokinetics, safety, and translational evidence. Apparent findings: CBC interacts with several transient receptor potential channels and has diverse preclinical signals, but oral bioavailability is low and human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are absent. Limitations and uncertainty: a broad review of mostly preclinical evidence cannot establish clinical efficacy, dosing, safety, or an [entourage effect](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) in patients. Why noteworthy: it provides a useful boundary between growing commercial interest in minor cannabinoids and the much thinner clinical evidence base. How Strong Is This Evidence? All ten records were verified through PubMed metadata with authors, journal, publication information, PMID, and DOI. The strongest direct clinical relevance comes from two case reports and a human questionnaire study, while most of the set is methodological, preclinical, or review evidence. Where This Paper Deserves Skepticism A case can suggest, a reliability study can improve measurement, a methods paper can strengthen testing, and an animal model can probe mechanism. None of those designs supplies the comparative human evidence needed for a treatment recommendation. What This Paper Does Not Show This digest does not establish cannabinoid treatment efficacy, identify a safe prenatal THC exposure, prove that adolescent THC causes schizophrenia, show that CBD substitutes for hormone therapy, or demonstrate that CBC or CB2-targeting therapies work in patients. How This Fits With the Broader Clinical Conversation [Cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) now spans clinical care, toxicology, product testing, developmental biology, immunology, and minor cannabinoids. Progress depends on matching claims to design and then testing promising signals in appropriately controlled human studies. Dr. Caplan’s Take *A useful digest should not flatten ten different designs into one conclusion. The case reports may change what a clinician asks. The methods papers may change how researchers measure exposure. The animal studies may change the next experiment.* *What these papers should not change is the standard for clinical proof. Biological plausibility and interesting observations deserve attention, but patients deserve a clear account of uncertainty.* What a Careful Reader Should Take Away Use this watchlist to ask better questions about safety, exposure, measurement, and mechanism. Do not use it as a substitute for controlled human evidence or individualized medical advice. Evidence Interpretation Guide ## How to Read Ten Different Study Designs Without Overstating Them The papers answer different kinds of questions. Their conclusions should remain proportional to the study design and measured outcome. ### Four checks for a careful reading **Identify the evidence level**Separate case reports, measurement studies, laboratory methods, animal experiments, and reviews before interpreting the findings. **Name the measured outcome**Symptom resolution, test-retest agreement, tissue concentration, gene expression, and behavior are not interchangeable outcomes. **Keep species and setting visible**Findings in rodents, explants, or laboratory matrices do not automatically predict human clinical effects. **Ask what comparison is missing**Without a control group, replication, or a human trial, a promising observation remains provisional. Key Reading Question What did this paper directly measure, and what stronger study would be needed before changing care? The Patient Question Is this evidence about people like me, or is it a case, laboratory method, animal model, or review? The Bottom Line Interesting science becomes clinically useful only when its limits remain visible. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives on using a broad cannabis-science watchlist responsibly. #### Ask What Kind of Evidence This Is A case report and an animal study cannot answer the same clinical question. Ask whether people with your condition were actually studied. Lens takeaway Evidence type changes what the result can mean. #### Use Signals to Improve the History Cannabinoid hyperemesis and perioperative respiratory events make route, frequency, and timing clinically relevant. They do not create a universal risk estimate. Lens takeaway Better questions are an immediate clinical benefit. #### Measurement Quality Matters Reliable questionnaires and validated laboratory methods shape the safety evidence clinicians eventually receive. Poor exposure measurement can obscure real risks. Lens takeaway Methods are part of clinical evidence quality. #### Animal Transfer Is Not a Human Threshold THC reached fetal brain tissue in two animal species. The study does not identify a safe human exposure or predict a child’s outcome. Lens takeaway Exposure evidence requires cautious translation. #### Models Test Plausibility Mouse studies can isolate developmental timing and interacting biological risks. They cannot diagnose a human psychiatric disorder. Lens takeaway Mechanism is not destiny. #### Commercial Interest Exceeds Clinical Evidence CBC has extensive preclinical discussion but no established human efficacy base. Product availability does not substitute for trials. Lens takeaway Novelty should not be confused with proof. #### Promising Is Not Proven Reviews can organize evidence and still rest mainly on preclinical studies. Case outcomes can be compelling and still be uncontrolled. Lens takeaway Scale the claim to the design. #### Move Toward Comparative Human Outcomes Replication, validated exposure measures, dose characterization, and controlled human studies are recurring needs. Clinically meaningful endpoints should lead the next evidence stage. Lens takeaway The next study should close a specific uncertainty. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Digest+Post%3A+10+interesting+recent+studies&url=https%3A%2F%2Fcedclinic.com%2Fdigest-post-10-interesting-recent-studies%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdigest-post-10-interesting-recent-studies%2F) [BlueSky](https://bsky.app/intent/compose?text=Digest+Post%3A+10+interesting+recent+studies%20https%3A%2F%2Fcedclinic.com%2Fdigest-post-10-interesting-recent-studies%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary sources: ten recent peer-reviewed PubMed records](https://pubmed.ncbi.nlm.nih.gov/42491286/) Related Reading at CED Clinic Continue exploring the evidence [Cannabinoid Hyperemesis Syndrome: ED Treatment Guide 2025](https://cedclinic.com/cannabis-hyperemesis-syndrome-diagnosis-ed-visits-surge/) Earlier CED context on recognizing and managing cannabinoid hyperemesis in acute care. [Read the CHS treatment context](https://cedclinic.com/cannabis-hyperemesis-syndrome-diagnosis-ed-visits-surge/) [Prenatal Cannabis Exposure and Neurodevelopment](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/) CED review of human prenatal cannabis evidence and its major confounding and interpretation limits. [Read the prenatal evidence review](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/) [Comparative Pharmacokinetic Parameters of CBC, THC, and CBD](https://cedclinic.com/comparative-pharmacokinetic-parameters-of-cbc-thc-and-cbd/) Earlier CED context on cannabichromene pharmacokinetics and the limits of minor-cannabinoid evidence. [Read the CBC context](https://cedclinic.com/comparative-pharmacokinetic-parameters-of-cbc-thc-and-cbd/) ## Frequently Asked Questions Are these ten studies all [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/)? No. The set includes case reports, a questionnaire reliability study, a laboratory methods paper, animal studies, and mechanistic reviews. Does topical capsaicin cure cannabinoid hyperemesis syndrome? One case reported rapid improvement, but a single uncontrolled case cannot establish universal effectiveness. Stopping cannabis remains central to preventing recurrence. Does cannabis vaping cause postoperative hypoxemia? The case report raises a possible association but cannot establish causation or quantify risk. Does a reliable questionnaire prove that cannabis treats chronic pain? No. Reliability means responses were reasonably repeatable. It does not establish objective accuracy or treatment benefit. Why does cannabis heavy-metal testing matter clinically? Testing quality affects whether arsenic, cadmium, lead, and mercury contamination is detected accurately in cannabis products. Did the prenatal study involve humans? No. It used pregnant prairie voles and rats to measure THC transfer into maternal and fetal tissues. Does the schizophrenia mouse study prove THC causes schizophrenia? No. It tests biological plausibility in a specific animal model and cannot establish an individual human outcome. Is CBD equivalent to hormone therapy for menopause symptoms? No. Similar findings in an ovariectomized-rat experiment do not establish equivalence, efficacy, or safety in humans. Is CB2 already a proven treatment target for [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/)? No. The review describes mechanistic and preclinical evidence that still requires controlled human validation. Is CBC clinically proven? No. The review describes substantial preclinical interest but notes the absence of human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) establishing efficacy. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).